title: Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
abstract: In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol (DES) (3 mg/day) for 4 weeks prior to the first injection of the LHRH agonist Zoladex (3.6 mg depot form) prevented any rise in the serum testosterone concentration. In contrast, in the groups pre-treated with DES, the first, but not subsequent, injections with Zoladex were associated with a marked surge in luteinising hormone. Treatment with DES beyond the time of the first administration of Zoladex did not provide further endocrinological advantage. Oestrogen priming for 1 month prior to treatment with Zoladex may prevent an exacerbation of signs and symptoms of prostate cancer.
authors.affiliation: Department of Medicine, North Shore University Hospital, Cornell University Medical College, Manhasset, NY.
authors.forename: W
authors.initials: W
authors.lastname: Kreis
authors.forename: F R
authors.initials: FR
authors.lastname: Ahmann
authors.forename: V C
authors.initials: VC
authors.lastname: Jordan
authors.forename: H
authors.initials: H
authors.lastname: de Haan
authors.forename: M
authors.initials: M
authors.lastname: Scott
mesh_terms: D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*
chemical_list: D017273:Goserelin; D013739:Testosterone; D004054:Diethylstilbestrol; D007986:Luteinizing Hormone; D002064:Buserelin